for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Geron Corporation

GERN.O

Latest Trade

1.38USD

Change

-0.10(-6.76%)

Volume

2,306,546

Today's Range

1.38

 - 

1.51

52 Week Range

1.20

 - 

2.36

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.48
Open
1.51
Volume
2,306,546
3M AVG Volume
37.59
Today's High
1.51
Today's Low
1.38
52 Week High
2.36
52 Week Low
1.20
Shares Out (MIL)
321.95
Market Cap (MIL)
476.48
Forward P/E
-4.35
Dividend (Yield %)
--

Next Event

Q4 2021 Geron Corp Earnings Release

Latest Developments

More

Geron Publishes Analysis Of IMbark Phase 2 In Annals Of Hematology

Geron Corporation Reports Greater Than 90% Enrollment In Imerge Phase 3 And Expected Top-Line Results Accelerated To First Quarter Of 2023

Geron Posts Q1 Loss Per Share Of $0.09

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Geron Corporation

Geron Corporation is a late-stage clinical biopharmaceutical company, which is focused on the development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. The Company operates through a single segment, which is engaged in the development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat include IMerge, a Phase III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis. Its IMpactMF is an ongoing Phase III clinical trial in refractory myelofibrosis (MF).

Industry

Biotechnology & Drugs

Contact Info

919 EAST HILLSDALE BOULEVARD, SUITE 250

FOSTER CITY, CA

94404

United States

+1.650.4737700

http://www.geron.com

Executive Leadership

John A. Scarlett

Chairman of the Board, President, Chief Executive Officer

Olivia K. Bloom

Chief Financial Officer, Executive Vice President - Finance, Treasurer

Andrew J. Grethlein

Executive Vice President, Chief Operating Officer

Stephen N. Rosenfield

Executive Vice President, Corporate Secretary, Chief Legal Officer

Anil Kapur

Executive Vice President, Corporate Strategy and Chief Commercial Officer

Key Stats

1.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-0.150

2019

-0.360

2020

-0.280

2021(E)

-0.340
Price To Earnings (TTM)
--
Price To Sales (TTM)
1,182.34
Price To Book (MRQ)
3.13
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
22.88
LT Debt To Equity (MRQ)
22.88
Return on Investment (TTM)
-47.71
Return on Equity (TTM)
-41.90

Latest News

Latest News

BRIEF-EcoR1 Capital LLC Reports 9.1% Passive Stake In Geron Corp

* ECOR1 CAPITAL LLC REPORTS 9.1% PASSIVE STAKE IN GERON CORP, AS OF MAY 22, 2020 Source text: (https://bit.ly/3cdjVV9) Further company coverage:

BRIEF-Geron Posts Q1 Loss Per Share Of $0.08

* Q1 EARNINGS PER SHARE ESTIMATE $-0.12 -- REFINITIV IBES DATA

BRIEF-Geron Corp Announces The Pricing Of Its Public Offering Of Common Stock And Warrants

* GERON CORPORATION ANNOUNCES THE PRICING OF ITS PUBLIC OFFERING OF COMMON STOCK AND WARRANTS

BRIEF-Geron Corporation Announces Proposed Public Offering Of Common Stock And Warrants

* GERON CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS Source text for Eikon: Further company coverage:

BRIEF-Geron Announces Plans For Imetelstat Phase 3 Clinical Trial In Myelofibrosis

* GERON ANNOUNCES PLANS FOR IMETELSTAT PHASE 3 CLINICAL TRIAL IN MYELOFIBROSIS AND OTHER UPDATES

BRIEF-Geron Corp Expects Spending In 2020 Will Be Lower Than $70 To $75 Mln Previously Guided

* GERON CORP - NO LONGER EXPECT TO COMPLETE ENROLLMENT IN IMERGE PHASE 3 TRIAL

BRIEF-Geron Reports Q4 Loss Per Share Of $0.15

* ORATION REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND 2020 MILESTONES

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up